Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGD Hydrogel for Vertical Ridge Augmentation
NCT07028606Phase 1Active, not recruiting
- Sponsor
- Al-Azhar University
- Start
- May 2024
- Primary completion
- May 2025
- Modality
- Peptides, Hydrogel Systems, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial in Alveolar bone loss (2 arms), sponsored by Al-Azhar University. Primary endpoint: Effect of RGD on volumetric bone changes. Started May 2024; status: active, not recruiting.
02
Conditions
Alveolar bone loss
Beyond the preview
Go deeper on NCT07028606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07028606.